Full Press Release Details
VANCOUVER, British Columbia and WARMINSTER, Pa., Sept. 22, 2017 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced presentation of HBV data at the following scientific conferences.
Discovery on Target: Targeting HBV, Sept 25, 2017, Boston, MA
Presentations Include:
RNA Interference: A New Tool in the Toolbox for Treatment of HBV by Amy Lee, Senior Director, Research
HBV Capsid Assembly Inhibitors by Rene Rijnbrand, Vice President, Head of Biology
Discovery on Target: Emerging Oligonucleotide Therapeutics, Sept 27-28, 2017, Boston, MA
Presentation Includes:
RNAi Based Human Therapy for Chronic Hepatitis B Infection by Amy Lee, Senior Director, Research
These presentations will be available by visiting the Investor section of www.arbutusbio.com and selecting Events and Presentations.
Arbutus Biopharma Corporation is a biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic HBV infection. Arbutus is headquartered in Vancouver, BC, and has facilities in Warminster, PA. For more information, visit www.arbutusbio.com.
Senior Vice President, Corporate Affairs
Email: acutler@arbutusbio.com
Manager, Investor Relations
Email: ttolmie@arbutusbio.com